BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
10 nov. 2022 07h00 HE
|
BioXcel Therapeutics
IGALMI™ (dexmedetomidine) well-positioned for growth in 2023 based on increasing market access, efficient targeting, favorable market drivers, and sales force expansion in all major U.S. geographies ...
BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022
27 oct. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022
05 oct. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
07 sept. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
09 août 2022 07h00 HE
|
BioXcel Therapeutics
Commercially launched IGALMI™ (dexmedetomidine) sublingual film for the acute treatment of agitation in bipolar I or II disorder and schizophrenia in adult patients SERENITY III pivotal...
BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth Conference
03 août 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal
01 août 2022 07h00 HE
|
BioXcel Therapeutics
Multi-year-funded award to support a 160-patient, randomized-controlled study in patients undergoing opioid withdrawal treatmentOver 142 million opioid prescriptions dispensed in the U.S. in 20201More...
BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
26 juil. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors
05 juil. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., July 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences
07 juin 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., June 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...